Mode
Text Size
Log in / Sign up

mMRC dyspnea scale correlates with risk stratification and 1-year outcomes in acute pulmonary embolism patientsA Simple Breathing Score Predicts Your Risk After a Lung Blood Clot

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that mMRC dyspnea scale correlates with 1-year outcomes in acute pulmonary embolism patients.

This retrospective cohort study examined patients aged 18–80 years diagnosed with acute pulmonary embolism at a tertiary care center. The primary focus was the mMRC dyspnea scale as a tool for risk stratification and predicting 1-year adverse outcomes. These outcomes included in-hospital mortality, all-cause mortality after discharge, and hospital readmission. The follow-up period was 1 year.

Main results indicated that the mMRC dyspnea scale was significantly positively correlated with the risk stratification of acute pulmonary embolism. This correlation was statistically significant with a P value less than 0.05. Absolute numbers for outcomes were not reported in the available data.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. The study did not report a specific sample size or publication type. Limitations inherent to retrospective designs and the absence of a comparator group were not explicitly detailed in the provided text. Consequently, the certainty of the association is limited by the observational nature of the evidence.

A Simple Breathing Score Predicts Your Risk After a Lung Blood Clot

Imagine leaving the hospital after a scary blood clot in your lung. You still feel short of breath. You wonder: Is this normal? Or is my body warning me of more trouble ahead?

A new study suggests a simple breathing test can answer that question. It’s called the modified Medical Research Council dyspnea scale, or mMRC. It asks how breathless you feel during daily tasks. That single score may predict your risk of death or hospital return within a year.

Here’s why this matters now. Acute pulmonary embolism, or APE, happens when a blood clot blocks an artery in the lung. It’s common and can be deadly. About one in ten patients die within a month. Many more struggle with lingering breathlessness, fatigue, and fear. Current risk tools can be complex. They often rely on lab tests, imaging, and specialist scoring systems. That can delay decisions or leave patients confused.

But here’s the twist. A simple question about your breathing may carry surprising power. The mMRC scale is already used in lung disease. This study tested how well it works for pulmonary embolism.

Think of your lungs like a city’s traffic system. Blood vessels are roads. A clot is a sudden roadblock. Traffic backs up. Pressure rises. Your body tries to reroute blood, but it’s not easy. The mMRC scale is like a traffic sensor. It doesn’t show the exact roadblock. It shows how much the whole system is struggling. A higher score means more congestion and more strain on the heart.

The study looked back at patients treated at a large hospital between 2011 and 2023. It included adults aged 18 to 80 who were diagnosed with APE. Researchers grouped patients by standard risk categories and by their mMRC score. They tracked who died in the hospital, who died after discharge, and who was readmitted within one year. They then checked how well the mMRC score predicted these outcomes.

What did they find? The mMRC score rose as the pulmonary embolism risk increased. In plain terms, the more breathless a patient felt, the more likely they were in a higher-risk group. The score also predicted one-year problems. Patients with higher mMRC scores had more deaths and more hospital returns. The researchers found an optimal cut-off point that best separated low-risk from high-risk patients.

Here’s the catch. This was a single-center study. That means the results come from one hospital’s patients and practices. It’s a strong signal, but not the final word.

Experts in the field note that breathlessness is a key symptom in pulmonary embolism. A simple, patient-reported score can complement existing tools. It can help clinicians triage faster and guide follow-up. It may also empower patients to track their breathing and share clear information with their care team.

What does this mean for you? If you’ve had a pulmonary embolism, ask your doctor about your breathlessness. The mMRC scale is easy to use. It’s a short set of questions about daily activities. Your score can help your team understand your risk and plan care. It is not a replacement for medical judgment or testing. It is an extra tool to make sure you’re not overlooked.

This doesn’t mean this treatment is available yet.

The study has limitations. It was retrospective, looking back at medical records. It involved one hospital, so results may vary elsewhere. The patients were adults up to age 80, so findings may not apply to older adults or children. The scale relies on how patients describe their symptoms, which can vary.

What happens next? Researchers will need to test the mMRC scale in more hospitals and in different regions. They will compare it with other risk tools and see if using it improves patient outcomes. If it holds up, hospitals may add it to routine care. That could help more patients get the right support at the right time.

For now, the takeaway is clear. A simple breathing score may help predict who faces trouble after a lung blood clot. It’s quick, patient-friendly, and already in use for other lung conditions. Talk to your doctor. Share how your breathing feels during daily tasks. Together, you can use every tool available to stay safe and healthy.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThis study aimed to investigate the value of the modified Medical Research Council (mMRC) dyspnea scale in risk stratification and outcome assessment for patients with acute pulmonary embolism (APE).MethodsA retrospective analysis was performed using medical records from a tertiary care center between 2011 and 2023. The study included patients aged 18–80 years who were diagnosed with APE. Participants were categorized into groups based on pulmonary embolism risk stratification, mMRC dyspnea scale, and the presence or absence of adverse outcomes within 1 year, which included in-hospital mortality, all-cause mortality after discharge, and hospital readmission. The associations between the mMRC dyspnea scale and both APE risk stratification and 1-year adverse outcomes were evaluated. The predictive performance of the mMRC dyspnea scale for 1-year adverse prognosis was assessed using receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off threshold.ResultsThe study demonstrated that the mMRC dyspnea scale was significantly positively correlated with risk stratification of APE (P 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.